
Feature|Videos|January 9, 2025
Capacity and Surge Response Leading Into a State of Readiness
Sustaining pandemic readiness requires investment in workforce, infrastructure, and scalable manufacturing practices.
Advertisement
Episodes in this series

Declining pandemic readiness is cause for concern; as such, the panelists highlight the importance of maintaining manufacturing capacity, a skilled workforce, and robust health infrastructure. Sustainable practices, including leveraging flu vaccine systems, are recommended for better future preparedness.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
2
Cellares Extends Cell Therapy Automation Beyond T Cell Therapies
3
Containment to Protection: Packaging Trends Impacting Biopharma
4
FDA Clears Affinia’s AFTX-201 for Phase I/II BAG3 Cardiomyopathy Trial
5



